Lion TCR Clinched 'Most Promising Cell & Gene Therapy Startup in Asia' Award

Lion TCR Pte Ltd, clinical-stage biotech company specialized in the development and commercialization of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers, has been recognized as the ‘Most Promising Cell & Gene Therapy Startup in Asia’ category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022, organized by IMAPAC.

Related Keywords

Singapore ,Antonio Bertoletti ,Karolinska Institute ,Singapore Agency For Science ,Stanford University ,Research Development ,Pte Ltd ,Most Promising Cell ,Gene Therapy Startup ,Asia Pacific Cell ,Gene Therapy Excellence ,Gene Therapy World Asia ,Sheraton Tower ,Wai Lu En ,Sarene Koh ,Promising Cell ,Liver Cancer Therapy Using ,Professor Antonio Bertoletti ,Fast Track ,Orphan Drug Designations ,Pacific Cell ,Gene Therapy Excellence Awards ,Gene Therapy World Asia Conference ,Asia Pacific Bioprocessing Excellence Awards ,Wuxi Biologics ,Bioprocessing Excellence ,Viral Clearance ,Resume ,Careers ,Ion Tcr Clinched Most Promising Cell Amp Gene Therapy Startup In Asia Award ,Iospace ,Advice ,